Classification, grouping and pathway are three separate decisions
Manufacturers often convert the class on a CE certificate or home-market licence straight into a local class, or assume that a device that is not implanted and does not touch blood must be low risk. All five markets use a four-tier system, but tier names, the treatment of low-risk devices, assessment routes and the applicant entity differ. One wrong call changes the dossier, the budget and the launch date.
MediPass fixes the intended use first, then answers three questions for each market: which risk class the device falls into (classification); which models and accessories can share one application (grouping); and which assessment route that application takes (full, abridged or reliance on an existing approval). Each conclusion records the rule, clause and document version it rests on, and becomes the shared baseline for all five submissions.
